2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients
2seventy bio Inc Ordinary Shares TSVT
News
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy
Correction to 2seventy to Sell R&D Pipeline Article
2seventy to Sell R&D Pipeline to Regeneron, Focus on Abecma
Bristol Myers Gets Positive CHMP Opinion for Earlier Abecma Use
Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
2seventy Bio Shares Fall Premarket on Abecma Expansion Delay
FDA Advisory Panel to Meet on Earlier Use of Abecma From Bristol, 2seventy
2seventy bio cutting 176 jobs, search for new chief executive
United States